Paragraph IV Settlement and License Deal Revitalizes Cholesterol Lowering Drug

CTSW has successfully negotiated the settlement of a paragraph IV litigation regarding FENOGLIDE®, a cholesterol lowering drug, and simultaneously with such settlement closed the exclusive licensing of rights to FENOGLIDE® to a sublicensee.  The settlement and licensing arrangement cap a successful eighteen month effort for the rescue and relaunch of FENOGLIDE®.